| dc.description.abstract | Background: The increasing number of elderly population is currently an
important issue for the world. Indonesia is also experiencing an increase in
population. Physiological aging and aging due to oxidative stress in the long term
will have an impact on cellular response disorders that can cause aging of the
hippocampus and senility. Andaliman is one of the typical herbal plants from
North Sumatra which has been widely used as an antioxidant, anti-inflammatory,
anti-aging, anti-cancer and so on. Previous studies has been done on this plant, but
until now the effect of andaliman ethanol extract (Zanthoxylum acanthopodium
DC) has not been found on memory function in the elderly. This study aim to
investigated andaliman fruitethanol extraxt (EEBA) can be efficacious as an
alternative management of dementia in the elderly.
Objective: To analyze the effect of ethanol extract of andaliman fruit on MDA
levels, BDNF, VEGF, p16INK4a expression and hippocampal memory function
in aging model rat.
Methods: Laboratory explorations were carried out by extracting andaliman fruit
and phytochemical tests. The treatment group consisted of 4 groups K1= negatif
control (normal), K2= positif control (aging model rat), P1= aging model rat +
EEBA at dose 150mg/kgbb, P2= aging model rat + EEBA at dose 300mg/kgbb for
8 weeks. The aging model rats were induced with D-galactose at a dose of 150
mg/kgbb for 8 weeks. The examination of MDA levels using the Elisa technique,
BDNF and VEGF expressions using RT-PCR, p16INK4a expression using the
Immunohistochemical method and cognitive function using the Moris Water
Maze test. The data analysis was performed by Anova test and differences
between groups were carried out using t-independent test.
Results: The results showed a significant difference in MDA levels in EEBA at
dose of 300mg/kgbw compared to KP (p=0.01). BDNF expression tended to
increase in EEBA dose 300mg/kgbw compared to KP (p>0.05), as well as VEGF
expression tended to increase in treatment groups (EEBA doses 150 and
300mg/kgbw) compared to KP (p>0.05). There was a significant difference in the
expression of p16INK4a protein between the treatment groups (p=0.041), where
EEBA group at dose of 300mg/kgbw was better reduced p16INK4a expression
than EEBA at dose of 150mg/kgbw (p<0.05). There was an improvement in
memory function between the treatment groups with decreased swimming time
(p=0.026). The average time needed to find the hidden platform (escape latency)
for 5 days of exercise among the treatment groups showed a significant decreased
in travel time in EEBA group at a dose of 300mg/kgbw compared to KP (p<0.05). Conclusion: Administration of EEBA at a dose of 300mg/kgbw was better
reduced serum MDA levels, decreased of p16INK4a expression and improved
memory function in aging model rats. | en_US |
